Uterine Myxoid Inflammatory Myofibroblastic Sarcoma (MIMS) Harboring Pathogenic KRAS Mutations and Expressing ER, PR, and CD10.
Jin Xu, David Kushner, Paul S Weisman
✦ AI-curated · Sources linked
Case in brief
A 40-year-old woman presented with a uterine tumor characterized by a whorled architecture and myxoid stroma. Immunohistochemical analysis revealed positivity for CD10, estrogen receptor (ER), and progesterone receptor (PR), while next-generation sequencing identified pathogenic KRAS mutations. The tumor's bland appearance led to potential misdiagnosis as other uterine neoplasms. The case was successfully managed following diagnosis.
What made this case unusual
This case is notable for the presence of pathogenic KRAS mutations in myxoid inflammatory myofibroblastic sarcoma, which is a rare finding in uterine tumors.
Diagnostic / clinical pearl
Clinicians should be aware that myxoid inflammatory myofibroblastic sarcoma can mimic endometrial stromal tumors due to its bland morphology and immunohistochemical profile.
Why it matters
Recognizing the distinct features of myxoid inflammatory myofibroblastic sarcoma is crucial for accurate diagnosis and management, particularly in cases with overlapping characteristics with other uterine neoplasms.